期刊论文详细信息
Frontiers in Oncology
Human antibody VH domains targeting uPAR as candidate therapeutics for cancers
Oncology
Wei Li1  Margaret G. Hines1  Xiaojie Chu1  John W. Mellors2  Dimiter S. Dimitrov2  Ilya Lyakhov3 
[1] Center for Antibody Therapeutics, Division of Infectious Diseases, Department of Medicine, University of Pittsburgh Medical School, Pittsburgh, PA, United States;Center for Antibody Therapeutics, Division of Infectious Diseases, Department of Medicine, University of Pittsburgh Medical School, Pittsburgh, PA, United States;Abound Bio, Pittsburgh, PA, United States;Comp IL, LLC, Carnegie, PA, United States;
关键词: therapeutic antibody;    VH domain;    human uPAR;    DbTE (domain based bispecific T cell engager);    cancer;   
DOI  :  10.3389/fonc.2023.1194972
 received in 2023-03-27, accepted in 2023-07-24,  发布年份 2023
来源: Frontiers
PDF
【 摘 要 】

The high expression of uPAR has been linked to tumor progression, invasion, and metastasis in several types of cancer. Such overexpression of uPAR makes it a potential target for immunotherapies across common cancers such as breast, colorectal, lung, ovarian cancer, and melanoma. In our study, two high-affinity and specific human VH domain antibody candidates, designed as clones 3 and 115, were isolated from a phage-displayed human VH antibody library. Domain-based bispecific T- cell engagers (DbTE) based on these two antibodies exhibited potent killing of uPAR-positive cancer cells. Thus, these two anti-uPAR domain antibodies are promising candidates for treating uPAR positive cancers.

【 授权许可】

Unknown   
Copyright © 2023 Chu, Li, Hines, Lyakhov, Mellors and Dimitrov

【 预 览 】
附件列表
Files Size Format View
RO202311144202357ZK.pdf 2385KB PDF download
  文献评价指标  
  下载次数:22次 浏览次数:4次